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Abstract 
Background: While there is increasing evidence on the safety of artemisinin‑based combination therapy (ACT) for 
the case management of malaria in early pregnancy, little is known about the association between exposure to ACT 
during the first trimester and the effect on fetal growth.
Methods: Data were analysed from prospective studies of pregnant women enrolled in Mozambique, Burkina Faso 
and Kenya designed to determine the association between anti‑malarial drug exposure in the first trimester and 
pregnancy outcomes, including low birth weight (LBW) and small for gestational age (SGA). Exposure to anti‑malarial 
drugs was ascertained retrospectively by record linkage using a combination of data collected from antenatal and 
adult outpatient clinic registries, prescription records and self‑reported medication usage by the women. Site‑level 
data synthesis (fixed effects and random effects) was conducted as well as individual‑level analysis (fixed effects by 
site).
Results: Overall, 1915 newborns were included with 92 and 26 exposed to ACT (artemether–lumefantrine) and 
quinine, respectively. In Burkina Faso, Mozambique and Kenya at recruitment, the mean age (standard deviation) was 
27.1 (6.6), 24.2 (6.2) and 25.7 (6.5) years, and the mean gestational age was 24.0 (6.2), 21.2 (5.7) and 17.9 (10.2) weeks, 
respectively. The LBW prevalence among newborns born to women exposed to ACT and quinine (QNN) during 
the first trimester was 10/92 (10.9%) and 7/26 (26.9%), respectively, compared to 9.5% (171/1797) among women 
unexposed to any anti‑malarials during pregnancy. Compared to those unexposed to anti‑malarials, ACT and QNN 
exposed women had the pooled LBW prevalence ratio (PR) of 1.13 (95% confidence interval (CI) 0.62–2.05, p‑value 
0.700) and 2.03 (95% CI 1.09–3.78, p‑value 0.027), respectively. Compared to those unexposed to anti‑malarials 
ACT and QNN‑exposed women had the pooled SGA PR of 0.85 (95% CI 0.50–1.44, p‑value 0.543) and 1.41 (95% CI 
0.71–2.77, p‑value 0.322), respectively. Whereas compared to ACT‑exposed, the QNN‑exposed had a PR of 2.14 (95% 
CI 0.78–5.89, p‑value 0.142) for LBW and 8.60 (95% CI 1.29–57.6, p‑value 0.027) for SGA. The level of between sites 
heterogeneity was moderate to high.
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Background
Malaria in pregnancy is an important public health 
problem in malaria-endemic countries where pregnant 
women and their offspring have a higher risk of infec-
tion and sequelae. Malaria infection during pregnancy 
is associated with maternal anaemia and intra-uterine 
growth restriction (IUGR), leading to poor pregnancy 
outcomes such as low birth weight (LBW) and small for 
gestational age (SGA) [1, 2]. LBW is defined as a birth 
weight of live-born infant of less than 2500 g regardless 
of gestational age [3]. The SGA is the weight below the 
10th percentile of weight for the gestational age. Malaria 
accounts for 14 to 25% of LBW in sub-Saharan Africa [4–
6]. LBW is a result of a short gestational period, IUGR or 
a combination of both processes, and contributes globally 
to high neonatal and infant mortality and morbidity [1, 
3]. Particularly in sub-Saharan Africa (SSA), LBW neo-
nates are nine times more likely to die in the 1st month 
of life than a normal-weight baby [7, 8]. Infants who are 
growth-restricted experience higher rates of fetal and 
infant death, birth asphyxia, hypothermia, hypoglycae-
mia, meconium aspiration, and long-term neurological 
impairment [9].
Cohort studies in malaria-endemic areas show an 
association between malaria infection at an earlier ges-
tational age, i.e., in the first trimester, and adverse fetal 
growth, pregnancy outcome, duration of pregnancy, 
and placental weight at term [10, 11]. Walker et al. esti-
mated that 65.2% (95% CI 60.9–70.0) of placental malaria 
infections occur at the end of the first trimester, and 
called for targeting this period for prevention [4]. Mul-
tiple measures to prevent and treat malaria and its com-
plications during pregnancy are recommended. These 
preventive measures presently include the use of long-
lasting insecticide-treated nets (LLINs), administration 
of intermittent preventive treatment in pregnancy with 
sulfadoxine–pyrimethamine (IPTp-SP), and rapid diag-
nosis and management of malaria cases [12]. The World 
Health Organization (WHO) currently recommends the 
use of artemisinin-based combination therapy (ACT) for 
the treatment of uncomplicated P. falciparum malaria 
in pregnant women in their second or third trimester. 
ACT is presently only recommended by WHO in the first 
trimester if quinine cannot be used or in case of severe 
malaria where the benefit outweighs the potential risk. 
Quinine is recommended for uncomplicated malaria in 
the first trimester of pregnancy [13]. However, quinine 
therapy has been documented to be associated with 
low adherence due to tolerability (occurrence of tinni-
tus, hearing impairment, dizziness, and postural hypo-
tension) and need for multiple doses (3 times a day) for 
7 days [12, 14].
Findings from preclinical studies have reported that 
artemisinins are embryotoxic and teratogenic in multi-
ple animal species [15–18]. In settings where malaria is 
endemic and ACT is highly available in the market, it is 
likely that a woman will be inadvertently or intention-
ally exposed in the first trimester because, for example, 
women and health care providers may be unaware of a 
woman’s pregnancy status at the time of prescribing an 
anti-malarial [19–21]. Therefore, it is imperative to assess 
the safety of first trimester ACT exposures for a broad 
range of pregnancy outcomes. The assessment of safety 
of anti-malarial drug use during early pregnancy (ASAP) 
study was a multi-country prospective cohort study of 
pregnant women to evaluate whether ACT exposure in 
early pregnancy increases the risk of miscarriage, still-
births, congenital malformations, and LBW when com-
pared to current therapeutic options [22]. The risk of 
miscarriage, stillbirths and congenital anomalies has 
been reported elsewhere [23, 24]. This analysis aimed 
to evaluate the association between ACT exposure dur-
ing the first trimester of pregnancy and LBW and SGA 
among the offspring of pregnant women.
Methods
Study design
ASAP was a prospective cohort study of pregnant 
women, conducted under a single multi-centre study 
protocol at three SSA sites as part of Malaria in Preg-
nancy Consortium activities as previously published 
[22]. The sites were located in Asembo-Siaya County, 
Kenya Nanoro, Burkina Faso; and, Manhiça District, 
Mozambique. In all three sites, malaria transmission 
is intense and P. falciparum is the main species. All 
three ASAP sites have a health and demographic sur-
veillance system (HDSS) [25–28]. Within their defined 
communities, HDSS sites ensure recording of all vital 
Conclusion: ACT exposure during the first trimester was not associated with an increased occurrence of LBW or SGA. 
However, the data suggest a higher prevalence of LBW and SGA for children born to QNN‑exposed pregnancies. The 
findings support the use of ACT (artemether–lumefantrine) for the treatment of uncomplicated malaria during the 
first trimester of pregnancy.
Keywords: Low birth weight, Small for gestational age, Prospective cohort, Artemisinins, Sub‑Saharan Africa, 
Pharmacovigilance
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status (births, deaths and migration) and other demo-
graphic events such as pregnancy by full enumeration 
of the population at least twice a year using commu-
nity key informants [28]. Additional recruitment and 
data collection strategies were employed for the ASAP 
study to identify pregnancies, anti-malarial exposures, 
determine gestational age at the time of exposure to 
anti-malarials, monitor pregnancy outcomes, and sys-
tematically assess infant outcomes. The emphasis was 
placed on identifying first-trimester pregnancies by 
identifying and recruiting women as early as possible in 
pregnancy.
Pregnant women were identified through household 
visits, community key informants, and at antenatal care 
visits in a health facility within the HDSS catchment 
area. All identified pregnant women were invited to the 
antenatal care (ANC) clinics and assessed for eligibility. 
Following written consent, baseline information was col-
lected and data entered into a pregnancy register. Elec-
tronic records from outpatient and inpatient visits were 
recorded through the HDSS platform and linked to the 
study records to identify possible exposure to ACT and 
other anti-malarials during the first trimester of the preg-
nancy. For this analysis, only singleton newborns with 
birth weight collected within the first 7  days of life are 
included. Multiple methods were used for the ascertain-
ment of gestational age, including date of last menstrual 
period, fundal height, ultrasound, and Ballard Score as 
explained elsewhere [22]. Women were encouraged to 
deliver at the closest health facility where systems were in 
place to identify and link records. Also, deliveries occur-
ring outside the health facility were actively identified by 
close monitoring lists of probable delivery and home-
based visits or by notification from village informants 
and traditional birth attendants (TBAs) whereby a study 
staff team assessed cases delivered at home as soon as 
possible.
Anti‑malarial exposure group definition
The ascertainment of drug exposure included both pro-
spective and retrospective self-reported medication 
usage and linkage to treatment records at local health 
facilities of drug prescribing and dispensing. The pro-
cess of drug identification, self-reporting and record 
linkage with health facility data has been described else-
where [22]. Two or more sources were required to con-
firm anti-malarial exposure; unconfirmed exposures 
were excluded. The treatments of interest were ACT 
or quinine during the first trimester of pregnancy, i.e., 
weeks 2 to 13 (inclusive) from the last menstrual period. 
Artemether–lumefantrine was the only ACT used in the 
three sites.
Outcomes
The present analysis is restricted to birth weight, LBW 
and SGA among live births. LBW was defined as a birth 
weight of < 2500  g collected within the first 24  h of life 
[3]. Birth weights taken between 24 and 48 h and 48 to 
168 h after delivery were corrected by a factor + 2% and 
+ 4%, respectively, to obtain the estimated weight at birth 
[29–32]. SGA was defined as a corrected birth weight 
below the 10th percentile of weight for the gestational 
age using the INTERGROWTH reference curves [33, 
34]. Following a suggestion by the reviewers, the analysis 
of prematurity was conducted as a supplemental analysis. 
Prematurity was defined as a live birth before 37 com-
pleted weeks of gestation [35].
Statistical methods
Baseline characteristics were compared by site and by 
anti-malarial exposure to assess imbalances across sites 
and exposure groups. Frequencies were used for cat-
egorical variables and for numeric variables means and 
standard deviations. The prevalence of LBW and of SGA 
and the mean birth weight by exposure group in each site 
were computed. As measure of association, the mean 
difference (MD) was used for birth weight outcome and 
prevalence ratios (PR) for the prevalence of LBW and 
SGA. Two types of data synthesis of effect were per-
formed. One is the site-level aggregated through the use 
of both fixed effects and random effects meta-analysis. 
Inverse variance based weights were used and for zero 
events study, 0.5 continuity correction was employed. To 
assess the heterogeneity between sites the  I2 statistic was 
used [36].
The other data synthesis is based on patient-level 
data whereby linear (for MD) and log-binomial (for 
PR) regressions were used. All models included the site 
indicator as covariates. The age at recruitment, gravid-
ity, marital status, and education level were included in 
the adjusted analysis. The log-binomial regressions had 
convergence failure and data spasticity issues. Thus, a 
Bayesian implementation of the log-binomial with pos-
terior distributions approximated through Markov Chain 
Monte Carlo (MCMC) was performed in JAGS software 
[37–39]. Uninformative priors for the coefficients were 
set as normal distributions with 0 mean and 1000 vari-
ance, the MCMC were run with 3 chains of 100,000 itera-
tions with 10,000 iterations as burn-in, and 50 as the thin 
steps. The convergence was assessed through the Gelman 
and Rubin’s diagnostic (Rhat < 1.2), review of the trace-
plots (assess the mixture of the simulations) and autocor-
relation of the iterations [37, 38]. The significance level 
was set at 5%. Additional analyses and data preparation 
were performed on Stata v14 (StataCorp. 2015. Stata: 
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Release 14. Statistical Software. College Station, TX, 
USA: StataCorp LP), R [40]. The INTERGROWTH-21st 
software was used to produce the percentiles of weights 
for gestation age [33].
Ethical approval
The protocol was reviewed and approved by the Ethi-
cal Review Boards of the Kenya Medical Research Insti-
tute (KEMRI), US Centers for Disease Control and 
Prevention (CDC), National Bioethics Committee in 
Mozambique, Centre Muraz Institutional Ethics com-
mittee and National Ethics committee in Burkina Faso, 
Liverpool School of Tropical Medicine in the UK, and 
the Institutional Review Board of the University of 
Washington.
Results
A total of 2836 recruited women representing 2930 preg-
nancy outcomes and 1915 live births were included in the 
analysis (Fig. 1). Excluded from the analysis were records 
that lacked confirmation of anti-malarial exposure (271), 
birth weights collected past 7th day of life (221), those 
lost to follow-up (100), either miscarriages or stillbirths 
(139), either twins gestation or second pregnancy follow-
up (90) and other reasons (194) (Fig.  1). Each site con-
tributed similar numbers of subjects for analysis, 656, 
3 sites
2930 pregnancies from
2836 women
2512 pregnancies from
2457 women
Excluded:
271 Anmalarials exposure could not be confirmed
57 Anmalarials at 14-18 weeks
23 > 1 anmalarial in the first trimester
42 Unknown gestaonal age
25 Recruited at or aer pregnancy outcome
2183 Live births
Excluded:
66 Second baby on same women
84 Miscarriages
55 Sllbirths
100 Lost to follow up
24 Twins
1915 Live births included 
1543 weights collected in 
1st 24 hours of life
Excluded:
221 Birth weights collected aer 7th day of life
47 Missing weight
Fig. 1 Flow chart of the recruited participants in ASAP cohort included in this analysis, 2015
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669 and 590 live births from Burkina Faso, Mozambique 
and Kenya, respectively. Of the live births included in the 
analysis 80.6% (1543) had birth weight collected in the 
first day of life with across site values of 47.8% (282/590), 
92.2% (605/656), and 98.1% (656/669) in Kenya, Burkina 
Faso and Mozambique, respectively. The final sample in 
terms of anti-malarial exposure during the first trimes-
ter of pregnancy included 1797 live births not exposed to 
an anti-malarial, 92 exposed to ACT and 26 exposed to 
quinine.
Baseline characteristics
Demographic characteristics among participants are 
reported in Tables 1 and 2 per site and exposures, respec-
tively. The average age at recruitment of the pregnant 
women in Burkina Faso was 27.1 years, which is almost 
2 years older than in Kenya (25.7) and 3 years older than 
in Mozambique (24.2). There was 30.8% primigravidae in 
the quinine-exposed group compared to 25.0% among 
those who were ACT-exposed and 21.0% among the 
unexposed to anti-malarials group. Approximately 21.7% 
of deliveries were in-home deliveries in Kenya compared 
to 11.7% and 5.2% in Burkina Faso and Mozambique, 
respectively.
Birth weight outcome
Newborns at Burkina Faso’s site had on average a weight 
of 2875.9 g, compared to Mozambique’s and Kenya’s site 
with 3093.3  g and 3175.2  g, respectively. Figure  2 and 
Additional file 1: Table S4 show the aggregated data syn-
thesis of mean differences of weights. For birth weight 
collected in the 1st week of life, the pooled fixed effects 
mean-difference between ACT and non-exposed group 
was found to be 56.4 g (95% CI − 36.5 to 149.3, p-value 
0.234) whereas for random-effects it was 51.9 g (95% CI 
− 59.6 to 163.4, p-value 0.362), both values are not sig-
nificantly different from the null. These results did not 
appreciably differ from those collected only within the 
first 24 h of life (Fig. 2a and Additional file 1: Table S4). 
For the comparison between quinine and non-exposed 
(Fig. 2b and Additional file 1: Table S5), Kenya could not 
be included due to the lack of quinine exposure, the con-
tribution of the remaining sites gave both pooled fixed 
and random effects of a non-significant association of 
22.5 g (95% CI − 166.9 to 211.9, p-value 0.816) for birth 
weights collected in the first week. When examining 
just the birth weights collected within the first day of 
life the differences reduce in magnitude to just − 3.0  g 
and 9.8  g for fixed-effects and random-effects, respec-
tively. Figure 2c and Additional file 1: Table S6 show the 
comparison between quinine and ACT exposures. All 
associations are in the direction of higher birth weights 
for ACT although not statistically significant with the 
fixed-effects of − 82.5 g (95% CI − 300.1 to 135.0, p-value 
0.457) for birth weights collected in the first week. Except 
for quinine versus non-exposed comparison, the hetero-
geneity of all these associations is between moderate to 
high  (I2 above 25%).
Table 3 shows the mean difference for individual-level 
analysis. For the quinine versus ACT comparison using 
the birth weights collected within the first week of life the 
Table 1 Baseline characteristics of  pregnancies included 
for  low birth weight and  small for  gestational analysis 
per study site, ASAP cohort, 2015
Characteristic Burkina Faso Mozambique Kenya
N (%) N (%) N (%)
Total participants 656 (100) 669 (100) 590 (100)
Age at recruitment (years)
 Range 15.0–49.0 12.4–41.9 15.0–45.0
 Mean (SD) 27.1 (6.64) 24.2 (6.23) 25.7 (6.48)
 < 20 94 (14.3) 207 (30.9) 117 (19.8)
 20–24 158 (24.1) 184 (27.5) 160 (27.1)
 25–29 171 (26.1) 152 (22.7) 147 (24.9)
 30+ 233 (35.5) 126 (18.8) 166 (28.1)
Gravidity
 Primigravida 113 (17.2) 178 (26.6) 118 (20.0)
 1–3 pregnancies 307 (46.8) 395 (59.0) 297 (50.3)
 4 or more pregnan‑
cies
236 (36.0) 93 (13.9) 175 (29.7)
 Missing 0 (0.0) 3 (0.4) 0 (0.0)
Marital status
 Single 9 (1.4) 240 (35.9) 125 (21.2)
 Married or cohabit‑
ing
647 (98.6) 428 (64.0) 465 (78.8)
 Missing 0 (0.0) 1 (0.1) 0 (0.0)
Education
 Primary not com‑
pleted
0 (0.0) 96 (14.3) 268 (45.4)
 Primary completed 656 (100.0) 330 (49.3) 276 (46.8)
 Secondary com‑
pleted
0 (0.0) 241 (36.0) 46 (7.8)
 Missing 0 (0.0) 2 (0.3) 0 (0.0)
HIV status
 Negative 633 (96.5) 442 (66.1) 445 (75.4)
 Positive 4 (0.6) 164 (24.5) 125 (21.2)
 Missing 19 (2.9) 63 (9.4) 20 (3.4)
Gestational age at recruitment (weeks)
 Mean (SD) 24.0 (6.15) 21.2 (5.65) 17.9 (10.20)
 Median (IQR) 24.1 (19.6–28.7) 21.0 (17.0–25.0) 15.9 (9.1–26.0)
Place of delivery
 Health facility 579 (88.3) 611 (91.3) 424 (71.9)
 Home 77 (11.7) 35 (5.2) 128 (21.7)
 Other 0 (0.0) 23 (3.4) 38 (6.4)
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unadjusted mean difference was 108.0 g (95% CI − 341.2 
to 125.1, p-value − 0.361) in favour of the ACT group. 
This MD increased slightly in favor of the ACT with a 
value of − 167.7 g (95% CI − 391.6 to 56.1, p-value 0.140) 
when adjusted for other covariates.
LBW outcome
The prevalence of LBW was 15.9% (104/656), 6.1% 
(41/669) and 7.2% (43/590) in Burkina Faso, Mozam-
bique and Kenya, respectively. Figure 3 shows the pool-
ing of the site-aggregated data. Relative to non-exposed, 
newborns exposed to ACT (Fig. 3a and Additional file 1: 
Table  S7) with weight collected in the first week of life 
had 1.13 (95% CI 0.62–2.05, p-value 0.700) times higher 
prevalence of LBW through the fixed-effects estimate. A 
similar magnitude was found through the random-effects 
estimate. In Kenya, there was no quinine exposure. Rela-
tive to non-exposed newborns, quinine exposed had 2.03 
(95% CI 1.09–3.78, p-value 0.027) times higher preva-
lence of LBW through the fixed-effects estimate (Fig. 3b 
and Additional file 1: Table S8). A similar association was 
found through the random-effects. Compared to ACT, 
Table 2 Baseline characteristics by exposure level (no exposure, exposed to ACT, exposed to quinine), ASAP cohort, 2015
SD standard deviation
Characteristic No anti‑malarial use in first 
trimester
Confirmed ACT use in first 
trimester
Confirmed quinine use 
in first trimester
All pregnancies
N (%) N (%) N (%) N (%)
Total 1797 (100) 92 (100) 26 (100) 1915 (100)
Country
 Burkina Faso 603 (33.6) 31 (33.7) 22 (84.6) 656 (34.3)
 Mozambique 643 (35.8) 22 (23.9) 4 (15.4) 669 (34.9)
 Kenya 551 (30.7) 39 (42.4) 0 (0.0) 590 (30.8)
Age at recruitment (years)
 Range 12.4–49.0 15.0–45.0 17.0–36.0 12.4–49.0
 Mean (SD) 25.7 (6.55) 25.6 (6.63) 24.7 (6.04) 25.6 (6.54)
 < 20 394 (21.9) 17 (18.5) 7 (26.9) 418 (21.8)
 20–24 465 (25.9) 30 (32.6) 7 (26.9) 502 (26.2)
 25–29 444 (24.7) 19 (20.7) 7 (26.9) 470 (24.5)
 30+ 494 (27.5) 26 (28.3) 5 (19.2) 525 (27.4)
Gravidity
 Primigravida 378 (21.0) 23 (25.0) 8 (30.8) 409 (21.4)
 1–3 pregnancies 943 (52.5) 45 (48.9) 11 (42.3) 999 (52.2)
 4 or more pregnancies 473 (26.3) 24 (26.1) 7 (26.9) 504 (26.3)
 Missing 3 (0.2) 0 (0.0) 0 (0.0) 3 (0.2)
Marital status
 Single 354 (19.7) 20 (21.7) 0 (0.0) 374 (19.5)
 Married or cohabiting 1442 (80.2) 72 (78.3) 26 (100.0) 1540 (80.4)
 Missing 1 (0.1) 0 (0.0) 0 (0.0) 1 (0.1)
Education
 Primary not completed 348 (19.4) 16 (17.4) 0 (0.0) 364 (19.0)
 Primary completed 1176 (65.4) 62 (67.4) 24 (92.3) 1262 (65.9)
 Secondary completed 271 (15.1) 14 (15.2) 2 (7.7) 287 (15.0)
 Missing 2 (0.1) 0 (0.0) 0 (0.0) 2 (0.1)
HIV status
 Negative 1427 (79.4) 70 (76.1) 23 (88.5) 1520 (79.4)
 Positive 279 (15.5) 13 (14.1) 1 (3.8) 293 (15.3)
 Missing 91 (5.1) 9 (9.8) 2 (7.7) 102 (5.3)
Gestational age at recruitment (weeks)
 Mean (SD) 21.3 (7.39) 18.8 (8.72) 16.8 (5.56) 21.2 (7.88)
Gestational age at delivery (weeks)
 Mean (SD) 38.9 (1.80) 39.0 (1.77) 38.8 (1.65) 38.9 (1.79)
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Fig. 2 Weight at birth mean difference in grams for different sites and random‑effects pooled association, ASAP study
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the quinine-exposed newborns had a non-significant 2.14 
(95% CI 0.78–5.89, p-value 0.142) times higher preva-
lence of LBW through the fixed-effects analysis. Similar 
results were obtained on the random-effects analysis. 
Furthermore, this association becomes stronger, although 
marginally significant when restricting to weights col-
lected within the first 24 h of birth (Fig. 3c and Additional 
file 1: Table S9). A small heterogeneity was observed for 
LBW aggregated analysis with all  I2 below 15%.
Table 4 shows the results of the individual-level analy-
sis for the LBW outcome. There were no differences in 
the prevalence of LBW for pregnancies treated with qui-
nine compared to those treated with an ACT in the first 
trimester (unadjusted PR 2.03, 95% CI 0.73–5.86, p-value 
0.172). The association reduced to 1.70 (95% CI 0.60–
5.17, p-value 0.321) with adjustment for covariates.
Small for gestational age and prematurity
The prevalence of SGA was 19.1% (124/648), 5.0% 
(33/659) and 19.6% (114/581), respectively in Burkina 
Faso, Mozambique and Kenya. Figure  4 and Additional 
file  1: Tables S10–S12 show the forest plots for the site 
aggregated analysis for SGA prevalence ratio. Across 
the three sites, quinine-exposed newborns had a 41% 
(1.41, 95% CI 0.72–2.77, p-value 0.322) relatively higher 
prevalence of SGA than non-exposed under the fixed-
effects pooling (Fig. 4b and Additional file 1: Table S11). 
The magnitude of the association increased to 8.60 (95% 
CI 1.29–57.57) for the quinine versus ACT comparison 
(Fig.  4c). Pregnancies treated with ACT during the first 
trimester were not associated with an increased preva-
lence of SGA compared with pregnancies not treated 
with an anti-malarial (PR 0.85, 95% CI 0.50–1.44) 
(Fig. 4a).
Table 4 shows the individual level based analysis for the 
SGA prevalence. On the unadjusted analysis, quinine-
exposed compared to ACT-exposed newborns had 13.75 
times higher prevalence of SGA with a wide confidence 
interval (2.16–409.72) not including the null, with similar 
results under the adjusted analysis.
The prevalence of prematurity was 6.6% (43/656), 9.8% 
(65/665) and 3.2% (19/590) respectively in Burkina Faso, 
Mozambique and Kenya. Figure  5 and Additional file  1: 
Tables S13–S15 show the forest plots for the site aggre-
gated analysis for prematurity prevalence ratio. Across 
the all sites, under the fixed-effects pooling none of the 
associations between either ACT- or quinine-exposed 
newborns, and prematurity reached statistical signifi-
cance (Fig.  5b, c and Additional file  1: Tables S14 and 
S15). The individual level based analysis did not mean-
ingfully change the results (Additional file 1: Table S16).
Discussion
No evidence was found of an increased risk of LBW, 
SGA or prematurity among pregnancies with a con-
firmed exposure to ACT for malaria treatment during 
the first trimester of pregnancy is not associated with an 
increased risk of LBW, SGA and prematurity compared 
to newborns unexposed to anti-malarials. The findings 
on ACT use in early pregnancy and fetal growth add 
reassurance to the previously documented safety pro-
file of ACT used during early pregnancy in many SSA 
countries [19, 41–43]. A meta-analysis that incorporated 
studies in SSA and Asia provided further evidence on the 
safety of ACT and the risk of miscarriages, stillbirth and 
congenital anomalies [24].
While infrequently used in this study, quinine exposure 
in the first trimester of pregnancy was associated with a 
Table 3 Adjusted associations for mean weight at birth
a Unadjusted regression includes dummy indicators for site
b Adjusted for site, age at recruitment, gravidity, marital status and education level
Mean difference in g (95% CI)
Unadjusteda p‑value Adjustedb p‑value
Birth weights measured within 24 h of birth (N) 1543 1533
 No exposure 0 (reference) 0 (reference)
 Artemisinin 37.8 (− 67.7; 143.3) 0.482 29.6 (− 62.0; 121.3) 0.526
 Quinine − 32.1 (− 207.9; 143.8) 0.721 − 29.0 (− 181.6; 123.6) 0.709
Birth weights measured within 7 days of birth (N) 1915 1905
 No exposure 0 (reference) 0 (reference)
 Artemisinin 34.9 (− 62.7; 132.5) 0.483 40.0 (− 47.8; 127.8) 0.371
 Quinine − 4.2 (− 185.7; 177.2) 0.964 − 3.6 (− 166.8; 159.6) 0.965
 Quinine vs artemisinin (N) 118 118
 Artemisinin 0 (reference) 0 (reference)
 Quinine − 108.0 (− 341.2; 125.1) 0.361 − 167.7 (− 391.6; 56.1) 0.140
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Fig. 3 ASAP site specific and pooled low birth weight prevalence ratios
Page 10 of 15Augusto et al. Malar J          (2020) 19:144 
twice higher prevalence of LBW when compared to the 
unexposed to anti-malarials group or ACT-exposed. This 
finding should be interpreted with caution since it may 
be due to small numbers in the sample or to inadequately 
treated malaria resulting from the known drawbacks 
with oral quinine related to poor tolerability character-
ized by tinnitus, hearing impairment, dizziness, and pos-
tural hypotension and need for multiple doses (3 times a 
day) for 7 days [14, 44], creating a channelling bias [45]. 
Furthermore, Mosha et  al. reported a trend towards a 
protective but non-significant association on LBW of 
quinine exposure in the first trimester of gestation [41].
There was no evidence of an increased prevalence of 
SGA with exposure to ACT. This finding is consistent 
with Manyando et al. who reported a similar prevalence 
of SGA among newborns exposed to ACT compared to 
exposed to sulfadoxine–pyrimethamine (9.0 vs 7.7%) in 
a cohort in Zambia and using a more restrictive defini-
tion of SGA (weight for gestational age below the fifth 
percentile). Also, there was no evidence of an increased 
prevalence of pre-term with exposure to ACT. However, 
quinine is possibly associated with a higher prevalence of 
SGA compared to those unexposed to anti-malarials or 
ACT in the first trimester of gestation. Previous literature 
comparing these risks is limited; this is the first study to 
investigate this association using the recently available 
world reference growth curves during gestation [19, 33].
Although malaria in pregnancy is common in SSA, it 
can be easily confused with many other febrile diseases 
that may occur during pregnancy. It has been shown in 
Table 4 Adjusted associations for low birth weight and small for gestational age
LBW low birth weight, SGA small for gestational age
a Unadjusted regression includes dummy indicators for site
b Adjusted for site, age at recruitment, gravidity, marital status and education level
c 95%CI—95% credible interval based on § posterior distribution replication
Prevalence‑ratio (95%  CIc)
Unadjusteda p‑value Adjustedb p‑value
LBW
 Birth weights measured within 24 h of birth (N) 1543 1533
  No exposure 1 (reference) 1 (reference)
  Artemisinin 0.80 (0.31; 1.62) 0.575 0.91 (0.36; 1.81) 0.809
  Quinine 1.95 (0.87; 3.42) 0.099 2.17 (1.00; 3.65) 0.049
 Birth weights measured within 7 days of birth (N) 1915 1905
  No exposure 1 (reference) 1 (reference)
  Artemisinin 1.08 (0.55; 1.85) 0.806 1.19 (0.61; 2.00) 0.579
  Quinine 1.87 (0.85; 3.27) 0.109 2.13 (0.98; 3.59) 0.055
  Quinine vs artemisinin
  Artemisinin 1 (reference) 1 (reference)
  Quinine with no Kenya data (N = 79) 2.03 (0.73; 5.86) 0.172 1.70 (0.60; 5.17) 0.321
  Quinine with Kenya data (N = 118) 3.18 (1.02; 11.56) 0.047 1.93 (0.72; 5.68) 0.188
SGA
 Birth weights measured within 24 h of birth (N) 1520 1514
  No exposure 1 (reference) 1 (reference)
  Artemisinin 0.76 (0.37; 1.31) 0.363 0.83 (0.41; 1.42) 0.516
  Quinine 1.31 (0.54; 2.43) 0.495 1.19 (0.50; 2.17) 0.660
 Birth weights measured within 7 days of birth (N) 1888 1882
  No exposure 1 (reference) 1 (reference)
  Artemisinin 0.81 (0.43; 1.31) 0.417 0.78 (0.43; 1.25) 0.337
  Quinine 1.29 (0.55; 2.40) 0.514 1.11 (0.47; 2.02) 0.789
  Quinine vs artemisinin
  Artemisinin confirmed 1 (reference) 1 (reference)
  Quinine confirmed with no Kenya data (N = 78) 13.75 (2.16; 409.72) 0.003 13.11 (1.82; 441.93) 0.004
  Quinine confirmed with Kenya data (N = 116) 14.44 (2.18; 400.29) 0.004 12.04 (1.84; 330.23) 0.008
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Fig. 4 ASAP site specific and pooled small for gestation age prevalence ratios
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Fig. 5 ASAP site specific and pooled prematurity prevalence ratios
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Mozambique that only 27% of pregnant women present-
ing with fever had parasitaemia detected [46]. Moreo-
ver, there might be a high self-perceived risk of malaria 
among pregnant women in settings such as the ones 
where the study was conducted. All this may lead to the 
treatment of unconfirmed malaria with ACT given its 
higher availability [47]. Particularly, in pregnancy when 
early weeks of gestation are not disclosed due to cul-
tural reasons or its unawareness, accidental anti-malarial 
exposure may occur more frequently than some studies 
have counted because only women with documented 
malaria are included [19, 41]. This calls for strengthening 
of pharmacovigilance systems in these settings.
The prevalence of SGA found in this study varied 
between 5.0% among infants born in Mozambique and 
19.6% among infants born in Kenya. These estimates 
are consistent with recent estimates of SGA based on 22 
birth cohort studies from the SGA-Preterm Birth work-
ing group [48]. However, a higher rate of SGA associated 
with P. falciparum infection was reported among preg-
nant women from the Thailand Myanmar border [49]. 
In this study, more than half of the women had their first 
antenatal visit during the second trimester of the preg-
nancy. This finding is very similar to DHS reports [50, 
51]. However, Asembo is an exception given that at least 
a third of the recruited women had the first antenatal 
visit in the first trimester. Starting antenatal care early 
during pregnancy increases the likelihood of initiating 
IPTp-SP and bed nets in accordance with guidelines and 
thereby reducing the occurrence of malaria and need for 
use of quinine and ACT. HDSS procedures mandate fre-
quent visits to a household. This increases the likelihood 
of detecting early pregnancies and facilitates follow-up of 
pregnancy outcomes. Nevertheless, cultural barriers [19] 
still pose challenges to the field workers to identify not 
yet visible pregnancies as almost half of the pregnancies 
were detected during the second semester.
Limitations
This study included only pregnancies ending as single-
ton live birth and with birth weight collected within 
7  days of life in the analysis. This could lead to some 
bias because SGA is associated with a lower probabil-
ity of survival. Thus, the inclusion in the data analy-
sis is conditioning on the outcome. However, it is not 
expected to be an important source of bias because the 
neonatal mortality rate in these sites is small (fewer 
than 30 per 1000 live-births). Compared to other study 
sites, Asembo (Kenya) had a higher proportion of miss-
ing information of weight at birth variable, represent-
ing 12% of all pregnancies recruited (Fig.  1). The vast 
majority of these missing birth weights are among 
newborns born at home, at which evaluation on the 
birthday was not possible. An imputation technique 
was used to mitigate this problem and the results did 
not materially change from the non-imputed scenario. 
However, the used imputation assumes that all new-
borns in one site are similar regardless of potential 
unmeasured biological differences (gender and mother 
anthropometrics). This may have contributed to lower 
prevalence of LBW because newborns who died due 
to conditions linked to LBW did not get their weights 
recorded and thus they do not contribute on the impu-
tation. However, it is not expected to have resulted in 
changing the overall direction of the associations. The 
ascertainment of the gestational age and weight at birth 
in the context of this study may have introduced some 
non-differential misclassification. While gestational 
age was assessed via multiple methods, as available and 
appropriate, including date of last menstrual period, 
Ballard Score, fundal height and ultrasound, there is 
no reason to believe that the accuracy of gestational 
age estimates varied by exposure status. Interviewers 
and study nurses were unaware of exposure status [22]. 
Similarly, weight at birth was recorded without knowl-
edge of exposure status.
Regarding birth weight, some newborns who were 
delivered in home settings had their weight assessed 
post-24  h of birth. If such non-differential misclassi-
fication occurred, it would have biased the estimates 
toward the null [19]. Nevertheless, the direction of the 
associations is the same as it was for the LBW. The sam-
ple size for quinine exposure is small and no exposures 
to quinine in Kenya were found. In addition, the main 
ACT used artemether–lumefantrine. Thus, one can-
not necessarily generalize these results to other ACT 
medicines. Furthermore, the data on the malaria epi-
sode being treated was limited and there could be a 
risk of confounding if there were differences in the type 
of underlying infections being treated by quinine and 
ACT. Also, the models could not be adjusted for HIV 
because of small counts for HIV positives.
Conclusions
No evidence was found of an increased risk of LBW, 
SGA or prematurity among infants born to women 
with confirmed first-trimester exposure to an ACT. The 
findings add support for the use of ACT for uncompli-
cated P. falciparum malaria during the first trimester of 
pregnancy. The existence of the HDSS platform greatly 
facilitated active safety surveillance of anti-malarials 
used during pregnancy.
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